longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.
Company profile
Ticker
LBPH
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
LBPH stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
15 Apr 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
PRE 14A
Preliminary proxy
28 Mar 24
8-K
Unregistered Sales of Equity Securities
26 Mar 24
S-8
Registration of securities for employees
12 Mar 24
S-3ASR
Automatic shelf registration
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
12 Mar 24
Transcripts
Latest ownership filings
SC 13G/A
FMR LLC
11 Mar 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
HBM Healthcare Investments (Cayman) Ltd.
13 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
4
Randall Kaye
9 Feb 24
4
Brandi Roberts
9 Feb 24
4
Kevin Robert Lind
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.91 mm | 23.91 mm | 23.91 mm | 23.91 mm | 23.91 mm | 23.91 mm |
Cash burn (monthly) | (no burn) | (no burn) | 4.53 mm | 4.41 mm | 4.43 mm | 4.13 mm |
Cash used (since last report) | n/a | n/a | 30.27 mm | 29.48 mm | 29.61 mm | 27.58 mm |
Cash remaining | n/a | n/a | -6.36 mm | -5.57 mm | -5.70 mm | -3.67 mm |
Runway (months of cash) | n/a | n/a | -1.4 | -1.3 | -1.3 | -0.9 |
Institutional ownership, Q3 2023
80.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 56 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 19 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 77.16 bn |
Total shares | 27.12 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
PFE Pfizer | 3.98 mm | $19.34 mm |
ARNA Arena Pharmaceuticals | 3.98 mm | $19.42 mm |
Cormorant Asset Management | 2.35 mm | $13.08 bn |
FMR | 2.11 mm | $11.75 bn |
T. Rowe Price | 1.77 mm | $9.86 mm |
Farallon Capital Management | 1.56 mm | $8.68 bn |
HBM Healthcare Investments | 1.35 mm | $0.00 |
Farallon Capital Partners | 1.17 mm | $0.00 |
Polar Capital | 1.00 mm | $5.56 bn |
Integrated Core Strategies | 987.71 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Jan 24 | Arena Pharmaceuticals | Voting Common Stock | Sell | Dispose S | No | No | 24.25 | 3,978,540 | 96.48 mm | 0 |
25 May 23 | Goff Corinne Le | Stock Option Voting common stock | Grant | Acquire A | No | No | 7.06 | 12,500 | 88.25 k | 12,500 |
25 May 23 | Schneider Phillip M | Stock Option Voting common stock | Grant | Acquire A | No | No | 7.06 | 12,500 | 88.25 k | 12,500 |
25 May 23 | Casey Lynch | Stock Option Voting common stock | Grant | Acquire A | No | No | 7.06 | 12,500 | 88.25 k | 12,500 |
25 May 23 | Jane Tiller | Stock Option Voting common stock | Grant | Acquire A | No | No | 7.06 | 12,500 | 88.25 k | 12,500 |
News
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
16 Apr 24
Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
10 Apr 24
Longboard Pharmaceuticals To Present Data From PACIFIC Study At AAN Annual Meeting On April 15
3 Apr 24
HC Wainwright & Co. Maintains Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
15 Mar 24
Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
13 Mar 24
Press releases
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
3 Apr 24
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2 Apr 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
12 Mar 24
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
1 Mar 24
Thinking about buying stock in ZIM Integrated Shipping, Solidion Technology, SoundHound AI, Longboard Pharmaceuticals, or Xpeng?
6 Feb 24